<DOC>
	<DOCNO>NCT02369848</DOCNO>
	<brief_summary>Shockwave Medical , Inc. intend conduct prospective , single-arm , multi-center , clinical study design evaluate safety performance Shockwave Lithoplasty™ System subject moderate heavily calcified peripheral artery 3.50mm 7.0mm reference vessel diameter target site . The Shockwave Lithoplasty™ System indicate generate sonic shockwave energy within target treatment site disrupt calcium within lesion allow subsequent dilation peripheral artery stenosis use low balloon pressure . Up sixty ( 60 ) subject enrol treat Lithoplasty yield thirty ( 51 ) evaluable subject complete study assume 15 % lose follow-up rate .</brief_summary>
	<brief_title>Shockwave Lithoplasty DISRUPT Trial PAD ( DISRUPT PAD 2 )</brief_title>
	<detailed_description>Shockwave Medical , Inc. intend conduct prospective , single-arm , multi-center , clinical study design evaluate safety performance Shockwave Lithoplasty™ System subject moderate heavily calcified peripheral artery 3.50mm 7.0mm reference vessel diameter target site . The Shockwave Lithoplasty™ System indicate lithotripsy-enhanced , low-pressure balloon dilation calcify , stenotic peripheral artery patient candidate percutaneous therapy . Up sixty ( 60 ) subject enrol 8 center Europe New Zealand yield least 51 evaluable subject ( assume lost-to-follow rate 15 % ) . Subjects evaluate discharge , 30 day , 6 month , 12 month enrollment/index procedure . Primary endpoint include safety efficacy . Safety composite new-onset Major Adverse Events 30 day . Efficacy target lesion patency 12 month duplex ultrasound define freedom ≥50 % restenosis .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Subject able willing comply assessment study . 2 . Subject subject 's legal representative inform nature study , agree participate sign approve consent form . 3 . Age subject &gt; 18 . 4 . Rutherford Clinical Category 2 , 3 , 4 . 5 . Resting anklebrachial index ( ABI ) ≤0.90 , ≤0.75 exercise , target leg . 6 . Estimated life expectancy &gt; 1 year . Angiographic 1 . Subject suitable candidate angiography endovascular intervention opinion investigator per hospital guideline . 2 . Target lesion locate native de novo superficial femoral artery ( SFA ) popliteal artery ( popliteal artery extend end proximal ostium anterior tibial artery ) . 3 . Target lesion reference vessel diameter 3.50mm 7.0mm visual estimate . 4 . Target zone ≤150mm length . Target lesion part 150mm zone . 5 . Target lesion ≥70 % stenosis investigator via visual estimate . 6 . Subject least one patent tibial vessel target leg runoff ankle ( supported collateral circulation . ) Tibial vessel patency define stenosis &gt; 50 % . 7 . Ability pas guidewire across atherosclerotic lesion . 8 . No evidence aneurysm acute chronic thrombus target vessel . 9 . Calcification least moderate . ( Presence fluoroscopic evidence calcification : 1 ) parallel side vessel 2 ) extend ≥ 50 % length lesion . ) 1 . Rutherford Clinical Category 5 6 . 2 . Subject active infection target leg . 3 . Planned major amputation target leg ( transmetatarsal high ) . 4 . The use chronic total occlusion ( CTO ) reentry device . 5 . CTOs great 80 mm length . 6 . Any instent restenosis within target zone . 7 . Lesions within 10 mm ostium SFA . 8 . Highly tortuous artery ( bend great 30 degree arc length balloon ) . 9 . Target lesion within native synthetic vessel graft . 10 . History prior endovascular surgical procedure index limb within past 30 day . 11 . Subject significant stenosis ( &gt; 50 % stenosis ) occlusion inflow tract target treatment zone ( e.g . iliac common femoral ) successfully treat POBA stent without complication . 12 . Subject require treatment peripheral lesion ipsilateral limb distal beyond 150mm target zone time enrollment/index procedure . 13 . Subject know coagulopathy bleeding diatheses , thrombocytopenia platelet count less 100,000/microliter , INR &gt; 1.5 . 14 . Subject antiplatelet , anticoagulant , thrombolytic therapy contraindicate . 15 . Subject know allergy contrast agent medication use perform endovascular intervention adequately pretreated . 16 . Subject know allergy urethane , nylon , silicone . 17 . Myocardial infarction within 60 day prior enrollment . 18 . History stroke within 60 day prior enrollment . 19 . History unstable coronary artery disease uncontrollable comorbidity result hospitalization within last 60 day prior enrollment . 20 . History thrombolytic therapy within two week enrollment . 21 . Subject acute chronic renal disease ( e.g. , measure serum creatinine &gt; 2.5 mg/dL &gt; 220 umol/L ) , dialysis . 22 . Subject pregnant nursing . 23 . Subject participate another research study involve investigational agent ( pharmaceutical , biologic , medical device ) reach primary endpoint . 24 . Subject medical , social psychological problem , opinion investigator , preclude receive treatment , procedure evaluation pre posttreatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>